Report Description

The Global Hormonal Contraceptives Market is anticipated to witness an impressive growth during the forecast period. This can be ascribed to the growing awareness regarding usage of oral contraceptive and its benefits for preventing the unintended pregnancy and population control significantly increased the demand for hormonal contraceptives across different parts of the globe. Additionally, adoption of hormonal contraceptives has significantly increased and increasing awareness among women of different age group for leading the safe life is further expected to increase the demand for different hormonal contraceptives procedures, thereby fuelling the market growth through 2028. For instance, in April 2021, the Food and Drug Administration approved a combination of drospirenone and estetrol tablet Nextstellis marketed by Mayne Pharma for preventing pregnancy, one of the first combination pills containing naturally occurring estrogen. Furthermore, increasing focus on family planning, favourable regulations by the government and advancements in hormonal contraception is further expected to increase the demand for hormonal contraceptives, thereby supporting the market growth. Similarly, supportive initiatives by various governments to increase to contraceptive products will propel the growth of the market during the forecast period. For instance, in July 2019, Allergen Plc collaborated with Ashley Tisdale, a musician, and actress, for the awareness campaign “Women Who Know”. According to the World Health Organization provided guidelines, for the usage of hormonal contraceptives, such as intrauterine devices, progestogen injectables, and implants, for women at greater risk of HIV. Hormonal contraceptives come in a variety of forms, including pills, patches, injections, vaginal rings, and implants. These methods are highly effective, with a failure rate of less than 1% when used correctly and consistently. Hormonal contraceptives can be expensive, especially in some regions, which makes them inaccessible to many women. Hormonal contraceptives can cause side effects such as nausea, headaches, and weight gain, which can discourage some women from using them. Religious and cultural beliefs that prevent the use of contraceptives can be a barrier to market growth in some regions. In some regions, hormonal contraceptives may not be readily available due to limited healthcare services or inadequate distribution networks. Hormonal contraceptives are not suitable for all women. Women who have a history of blood clots, breast cancer, liver disease, or certain other medical conditions may not be able to use hormonal contraceptives. It is important to consult with a healthcare provider to determine the best form of birth control for individual needs and circumstances.

Increasing Number of Unplanned Pregnancies

The main factors that affect the growth of the global hormonal contraceptives market are the increasing awareness on family planning due to growing urbanization, growing g influence for the changing lifestyle of individuals. Many government organizations are taking initiatives to control the population size. However, hormonal contraceptives are considered more reliable than non-hormonal contraceptives such as condoms and diaphragms, there is a huge chunk of the female population with unplanned needs. This in turn may help the hormonal contraceptives market growth during the forecast period. As per a publication in PubMed, the number of unintended pregnancies in the U.S are around three million annually. So, growing unplanned need for contraceptive significantly increased the demand which is further boosting the growth of the market in the forecast period. According to an NCBI research, only 1 woman out of 1000 women gets pregnant if they take these contraceptives properly. There is a growing awareness about the importance of family planning and the need for effective birth control methods to prevent unintended pregnancies. This is driving the demand for hormonal contraceptives as they are one of the most effective and convenient methods of birth control. The number of unintended pregnancies is on the rise globally. Hormonal contraceptives are an effective way to prevent unintended pregnancies and are therefore in high demand. With increasing urbanization and changing lifestyles, there is a growing need for effective birth control methods that are convenient and reliable. Hormonal contraceptives meet these requirements and are therefore preferred by many women.

Development of New Contraceptives

Major companies are innovating to manufacture a chewable low dose oral contraceptives that reduce side effects. Chewable contraceptive initiative was an attempt to reduce side effects while at the same time making it easier for the patients to get into a daily regimen of using this contraceptive. Some of the top companies that develop and sell chewable low-dose oral contraceptives are Lupin pharmaceuticals, Walter Chilcott and Watson pharmaceuticals. According to the United Nations Contraceptive Use by Method, 2019 study, a single method accounts for 50% or more of all contraceptive use in at least one out of every five nations or regions. LARCs such as intrauterine devices (IUDs) and implants are becoming increasingly popular as they offer a high level of effectiveness and convenience compared to traditional methods. This is driving the growth of the hormonal contraceptives market. Major players in the market are investing heavily in research and development to launch new products and improve the existing ones. For example, the recent launch of A-Z My Way by Merck & Co. is expected to drive the growth of the hormonal contraceptives market. The development of new hormonal contraceptives is necessary to meet the changing needs of women. Women have different preferences and needs when it comes to birth control, and new products need to be developed to offer a range of options that suit different lifestyles and medical needs. Hormonal contraceptives can have side effects, and the development of new products can help address these issues. For example, some women may experience mood changes, weight gain, or decreased libido when using hormonal contraceptives. Developing new products with different hormone combinations and dosages can help reduce side effects and increase user satisfaction. Hormonal contraceptives need to be convenient and easy to use to increase user adherence and effectiveness. The development of new products that offer longer-acting and more user-friendly options can help improve convenience and reduce the burden of daily pill-taking. The safety of hormonal contraceptives is important, and the development of new products is necessary to address safety concerns. New products need to be rigorously tested for safety and efficacy before they can be approved for use, and ongoing research is needed to monitor and improve the safety of hormonal contraceptives.

Recent Development

  • For instance, in April 2021, Mayne Pharma received U.S. FDA approval for NEXTSTELLIS and estetrol for avoiding pregnancy. It is the only contraceptive pill with E4 and a plant-based estrogen having few important benefits compared to other estrogens.
  • For instance, in July 2021, the MHRA launched the OTC sale of contraceptive pills in U.K. pharmacies. Two contraceptive pill brands, Hana and Lovima, are selling desogestrel- synthetic progesterone, OTC with a brief consultation with a pharmacist.
  • For instance, in June 2021, Teva Pharmaceuticals USA launched the generic form of NuvaRing, Ethinyl estradiol, and etonogestrel vaginal ring contraceptive.
  • In February 2020, Agile Therapeutics, Inc. received U.S. FDA approval for the Twirla, a transdermal patch containing levonorgestrel and Ethinylestradiol.
  • In recent years, several new hormonal contraceptives have been approved by regulatory agencies around the world. For example, in 2019, the US FDA approved Annovera, a new vaginal ring that can be used for a year, and in 2021, the FDA approved Phexxi, a non-hormonal contraceptive gel that can be used before sex. These new products offer women additional options for birth control and are likely to drive market growth.
  • As the demand for hormonal contraceptives grows in developing markets, several companies are expanding their operations to these regions. For example, in 2020, Merck announced plans to invest $500 million to expand its manufacturing operations in Asia and Africa. This move is expected to increase access to hormonal contraceptives in these regions and drive market growth.
  • Twirla is a new hormonal contraceptive patch that was approved by the US FDA in 2020. It contains the hormones progesterone and estrogen and is worn on the skin for a week at a time. It is a new option for women who prefer a non-pill form of hormonal contraception.
  • Sayana Press is an injectable contraceptive that was launched by Pfizer in 2019. It contains the hormone progestin and is administered subcutaneously. It is a more user-friendly and convenient option for women who want a longer-acting form of birth control.


Download Free Sample Report

Market Segmentation

The global hormonal contraceptives market can be segmented by method, by hormone and by region. Based on method, the market can be segmented into Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, Others. Based on hormone, the market can be divided into Combination Hormonal Contraceptives v/s Progestin Only. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United States dominated the global hormonal contraceptives market on account of increasing unplanned pregnancies with low-cost product in the country.

Market Players

Abbvie, Inc., Afaxys, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Merck & Co. Inc., Organon Group of Companies, Pfizer Inc., Johnson & Johnson, Lupin Pharmaceuticals Inc., Pregna International Ltd. are some of the leading players operating in the Global Hormonal Contraceptives Market.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028

Report Coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered

·         By Method

·         By Hormone

·         By Region

Regional scope

North America; Europe; Asia Pacific; South America; Middle East & Africa

Country scope

United States; Canada; Mexico; France; Germany; United Kingdom; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE; Turkey; Egypt

Key companies profiled

Abbvie, Inc., Afaxys, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Merck & Co. Inc., Organon Group of Companies, Pfizer Inc., Johnson & Johnson, Lupin Pharmaceuticals Inc., Pregna International Ltd.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Report Scope:

In this report, global hormonal contraceptives market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

        ·         Hormonal ContraceptivesMarket, By Method:

o    Pill

o    Intrauterine Device

o    Injectable

o    Vaginal Ring

o    Implant

o    Others

        ·         Hormonal ContraceptivesMarket, By Hormone:

o   Combination Hormonal Contraceptives

o   Progestin Only

        ·         Hormonal ContraceptivesMarket, By Region:

o    North America

§  United States

§  Canada

§  Mexico

o    Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o    Asia Pacific

§  China

§  India

§  Japan

§  South Korea

§  Australia

o    South America

§  Brazil

§  Argentina

§  Colombia

o    Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Turkey

§  Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Hormonal Contraceptives Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Hormonal ContraceptivesMarket is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Clinical Trial Analysis

5.1.  Ongoing Clinical Trials

5.2.  Completed Clinical Trials

5.3.  Terminated Clinical Trials

5.4.  Breakdown of Pipeline, By Development Phase

5.5.  Breakdown of Pipeline, By Status

5.6.  Breakdown of Pipeline, By Study Type

5.7.  Breakdown of Pipeline, By Region

5.8.  Clinical Trials Heat Map

6.    Global Hormonal Contraceptives Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Method (Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, Others)

6.2.2.     By Hormone (Combination Hormonal Contraceptives v/s Progestin Only)

6.2.3.     By Region

6.2.4.     By Company (2022)

6.3.  Market Map

6.3.1.     By Method

6.3.2.     By Hormone

6.3.3.     By Region

7.    North America Hormonal Contraceptives Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Method

7.2.2.     By Hormone

7.2.3.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Hormonal Contraceptives Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Method

7.3.1.2.2.             By Hormone

7.3.2.     Canada Hormonal Contraceptives Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Method

7.3.2.2.2.             By Hormone

7.3.3.     Mexico Hormonal Contraceptives Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Method

7.3.3.2.2.             By Hormone

8.    Europe Hormonal Contraceptives Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Method

8.2.2.     By Hormone

8.2.3.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Hormonal Contraceptives Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Method

8.3.1.2.2.             By Hormone

8.3.2.     Germany Hormonal Contraceptives Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Method

8.3.2.2.2.             By Hormone

8.3.3.     United Kingdom Hormonal Contraceptives Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Method

8.3.3.2.2.             By Hormone

8.3.4.     Italy Hormonal Contraceptives Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Method

8.3.4.2.2.             By Hormone

8.3.5.     Spain Hormonal Contraceptives Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Method

8.3.5.2.2.             By Hormone

9.    Asia-Pacific Hormonal Contraceptives Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Method

9.2.2.     By Hormone

9.2.3.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     China Hormonal Contraceptives Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Method

9.3.1.2.2.             By Hormone

9.3.2.     India Hormonal Contraceptives Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Method

9.3.2.2.2.             By Hormone

9.3.3.     Japan Hormonal Contraceptives Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Method

9.3.3.2.2.             By Hormone

9.3.4.     South Korea Hormonal Contraceptives Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Method

9.3.4.2.2.             By Hormone

9.3.5.     Australia Hormonal Contraceptives Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Method

9.3.5.2.2.             By Hormone

10.  South America Hormonal Contraceptives Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Method

10.2.2.  By Hormone

10.2.3.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Hormonal Contraceptives Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Method

10.3.1.2.2.           By Hormone

10.3.2.  Argentina Hormonal Contraceptives Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Method

10.3.2.2.2.           By Hormone

10.3.3.  Colombia Hormonal Contraceptives Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Method

10.3.3.2.2.           By Hormone

11.  Middle East and Africa Hormonal Contraceptives Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Method

11.2.2.  By Hormone

11.2.3.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Hormonal Contraceptives Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Method

11.3.1.2.2.           By Hormone

11.3.2.  Saudi Arabia Hormonal Contraceptives Market Outlook

11.3.2.1.      Market Size & Forecast